Prevention of Syncope (fainting) Trial 5
Summary
About 20% of adults faint recurrently. No treatments have been proven useful in adequately performed randomized clinical trials. This is a study to test the hypothesis that Metoprolol reduces the time to a first recurrence of syncope in patients ≥40 years old who have a high likelihood of recurrent fainting. This is a blinded placebo controlled study, which means that half the patients will receive metoprolol and half will get placebo. We will follow patients for a year.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 40 to 80
Inclusion criteria:
1. ≥1 faints in the year preceding enrolment
2. Vasovagal Syncope
3. Age ≥ 40 years.
Exclusion criteria:
(1) resting heart rate <50 bpm or supine systolic blood pressure <90 mm Hg in the absence of beta blockers or antihypertensive medications,
(2) other causes of syncope, such as sick sinus syndrome, ventricular tachycardia, complete heart block, postural hypotension or hypersensitive carotid sinus syndrome, (3) an inability to give informed consent,
(4) important valvular, coronary, myocardial or conduction abnormality,
(5) hypertrophic cardiomyopathy or known or probable genetic arrhythmia
(6) a contraindication to beta blockers such as asthma, insulin-dependent diabetes, severe depression, peripheral vascular disease, chronic obstructive pulmonary disease, or previous intolerance of beta blockers,
(7) another clinical need for beta blockers which can not be met with other drugs,
(8) a seizure disorder,
(9) major chronic non-cardiovascular disease,
(10) known hypersensitivity to metoprolol and derivatives
(11) an implanted defibrillator.
Participate
Additional information
Contact information
Shahana Safdar: 403-220-8897
Principal investigator:
Robert Stanley Sheldon
Clinical trial:
Yes
REB-ID:
REB13-1110